New: Evolving the Heatmap: Dow Jones, Nasdaq 100, Russell 2000, and More

Learn More
Last Close
Sep 18  •  11:08AM ET
10.08
Dollar change
+0.45
Percentage change
4.67
%
IndexRUT P/E46.95 EPS (ttm)0.21 Insider Own35.52% Shs Outstand79.59M Perf Week4.78%
Market Cap803.91M Forward P/E37.07 EPS next Y0.27 Insider Trans0.00% Shs Float51.42M Perf Month4.67%
Enterprise Value746.73M PEG0.87 EPS next Q0.02 Inst Own36.57% Short Float8.44% Perf Quarter-26.85%
Income17.73M P/S6.91 EPS this Y34.48% Inst Trans16.93% Short Ratio4.03 Perf Half Y30.23%
Sales116.30M P/B12.50 EPS next Y83.84% ROA24.36% Short Interest4.34M Perf YTD90.01%
Book/sh0.81 P/C13.29 EPS next 5Y53.78% ROE37.36% 52W High14.69 -31.38% Perf Year194.74%
Cash/sh0.76 P/FCF38.50 EPS past 3/5Y- - ROIC26.65% 52W Low3.18 216.98% Perf 3Y595.17%
Dividend Est.- EV/EBITDA39.34 Sales past 3/5Y13.87% 16.56% Gross Margin63.62% Volatility3.77% 4.09% Perf 5Y129.61%
Dividend TTM- EV/Sales6.42 EPS Y/Y TTM1370.00% Oper. Margin15.37% ATR (14)0.43 Perf 10Y135.79%
Dividend Ex-Date- Quick Ratio3.24 Sales Y/Y TTM35.89% Profit Margin15.24% RSI (14)56.52 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio3.88 EPS Q/Q21000.00% SMA203.85% Beta2.15 Target Price15.55
Payout0.00% Debt/Eq0.05 Sales Q/Q36.84% SMA502.17% Rel Volume0.60 Prev Close9.63
Employees104 LT Debt/Eq0.04 EarningsAug 06 AMC SMA20018.97% Avg Volume1.08M Price10.08
IPOJun 24, 2008 Option/ShortYes / Yes EPS/Sales Surpr.344.44% 9.92% Trades Volume185,759 Change4.67%
Date Action Analyst Rating Change Price Target Change
May-27-25Initiated Canaccord Genuity Buy $13
Aug-16-22Downgrade Oppenheimer Outperform → Perform
Aug-11-22Downgrade B. Riley Securities Buy → Neutral $6 → $2.40
Mar-08-22Initiated ROTH Capital Buy $7
Oct-16-19Initiated Oppenheimer Outperform $6
Feb-14-19Initiated B. Riley FBR Buy $7
Nov-27-17Resumed H.C. Wainwright Buy $6 → $8
Sep-25-17Initiated Ladenburg Thalmann Buy $7
Jan-03-17Initiated Rodman & Renshaw Buy $6
Sep-16-25 08:32AM
Aug-06-25 05:55PM
04:52PM
04:02PM
Aug-05-25 10:04AM
08:32AM Loading…
Aug-04-25 08:32AM
Jul-23-25 08:34AM
Jul-15-25 07:50AM
Jul-14-25 08:32AM
Jul-09-25 09:28AM
Jul-08-25 08:32AM
Jun-20-25 08:32AM
Jun-11-25 08:31AM
Jun-09-25 08:32AM
Jun-04-25 08:32AM
03:26AM Loading…
May-08-25 03:26AM
May-07-25 06:00PM
04:02PM
May-05-25 08:32AM
Apr-29-25 08:32AM
Apr-28-25 08:34AM
Apr-07-25 10:32PM
Mar-20-25 08:34AM
Mar-19-25 08:34AM
Mar-13-25 08:34AM
Mar-11-25 04:04PM
Mar-05-25 11:11AM
02:10AM
Mar-04-25 05:15PM
04:13PM
04:02PM Loading…
04:02PM
Mar-03-25 07:14AM
Feb-25-25 04:07PM
Jan-06-25 08:32AM
Dec-03-24 08:34AM
Nov-22-24 09:15AM
Nov-14-24 08:32AM
Nov-08-24 12:00PM
Nov-07-24 08:32AM
Nov-05-24 09:15AM
Nov-01-24 11:02AM
Oct-31-24 05:15PM
04:09PM
04:04PM
Oct-30-24 09:20AM
Oct-28-24 08:32AM
Oct-24-24 08:32AM
Oct-23-24 08:34AM
Oct-18-24 09:40AM
Oct-15-24 08:32AM
Oct-09-24 05:18PM
Sep-26-24 04:12PM
09:40AM
Sep-20-24 08:32AM
Sep-10-24 08:32AM
Sep-09-24 08:34AM
Aug-23-24 08:34AM
Aug-19-24 08:32AM
Aug-07-24 06:25PM
05:25PM
04:04PM
Aug-05-24 08:32AM
Jul-24-24 08:34AM
Jul-23-24 08:32AM
Jul-22-24 08:34AM
Jul-16-24 08:34AM
Jul-01-24 08:32AM
Jun-24-24 08:32AM
Jun-13-24 08:32AM
Jun-10-24 09:45AM
Jun-07-24 08:34AM
Jun-04-24 08:32AM
May-23-24 08:34AM
May-22-24 08:32AM
May-10-24 03:22PM
May-09-24 02:34PM
07:17AM
03:42AM
May-08-24 08:58PM
05:04PM
04:04PM
Apr-30-24 08:32AM
Apr-25-24 08:34AM
Apr-24-24 08:34AM
Apr-23-24 08:32AM
Mar-26-24 08:32AM
Mar-07-24 01:59PM
10:37AM
06:27AM
Mar-06-24 09:53PM
04:04PM
Feb-21-24 08:32AM
Feb-05-24 08:32AM
Jan-26-24 04:08PM
Dec-20-23 09:04AM
Dec-12-23 10:30AM
Nov-30-23 08:34AM
Nov-15-23 08:32AM
Nov-10-23 12:54PM
Nov-09-23 08:32AM
Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm's proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Fried Robert NChief Executive OfficerApr 09 '25Option Exercise3.3066,667220,0011,038,981Apr 09 07:52 PM
Lopez Carlos LuisSVP, General CounselMar 07 '25Buy7.862732,1462,251Mar 10 08:11 AM
Jaksch Frank L JrDirectorDec 13 '24Option Exercise3.6650,001183,004281,340Dec 13 07:12 PM
Jaksch Frank L JrDirectorDec 13 '24Sale6.1937,161229,956244,179Dec 13 07:12 PM
Frank Jaksch Jr.affiliateDec 13 '24Proposed Sale6.1937,161229,961Dec 13 01:54 PM
Pamir OzanChief Financial OfficerNov 22 '24Buy7.362,90721,3972,907Nov 25 07:28 AM